pharmacodynamic assay after single dose of gefitinib in resected adenocarcinoma of the lung

pharmacodynamic assay after single dose of gefitinib in resected adenocarcinoma of the lung - pharmacodynamic assay after single dose of gefitinib

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010462

Enrollment

Registered

2013-04-10

Start date

2013-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

take a gefitinib(250mg/body) two days before surgery no medication

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) histological or cytological confirmation of lung adenocarcinoma (NSCLC), class 4 or 5 2) planning of curative resection of NSCLC 3) non-smoker 4) 20 years or older 5) ECOG performance score of 0 or 1 6) informed written consent after understanding that this trial is not intended to treat the lung cancer 7) no prior therapy for NSCLC 8) preserved organ functions

Exclusion criteria

Exclusion criteria: 1) past history of severe allegy 2) clinically significant psychological problem 3) past or present history of interstitial lung disease detected by computed tomography 4) HIV infection 5) inadequate patient judged by a attending doctor

Design outcomes

Primary

Measure	Time frame
pharmacodynamic markers (apoptotic index, MIB-1 index, kinase activities) in surgical specimen	—

Countries

Japan

Contacts

Public Contactnaoki izawa

St. Marianna University School of Medicine Division of clinical oncology

n2izawa@gmail.com+81-44-977-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026